Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aldrich, M. S.
Right arrow Articles by Penney, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aldrich, M. S.
Right arrow Articles by Penney, J. B.
NEUROLOGY 1992;42:410
© 1992 American Academy of Neurology

Dopamine-receptor autoradiography of human narcoleptic brain

Michael S. Aldrich, MD, Zane Hollingsworth, MPH and John B. Penney, MD

Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI.

Although the pathology of human narcolepsy is unknown, studies of human and canine narcolepsy have suggested that dopamine metabolism may be disturbed. We used quantitative autoradiography to assess dopamine D1- and D2-receptor binding in basal ganglia and amygdala of five narcoleptic and 17 control human brains. In caudate, narcoleptic brains had a statistically significant increase of 57% in D1- receptor binding, and large but not significant increases of 54% in medial globus pallidus D1 binding, 63% in caudate D2-receptor binding, 95% in lateral globus pallidus D2 binding, and 93% in lateral amygdala D2 binding. We found no major changes in the putamen or in the basal or accessory basal nuclei of the amygdala. These results suggest that narcolepsy is associated with upregulation of dopamine receptors in specific areas of the brain, although medications used prior to death may have contributed to the findings.

Address correspondence and reprint requests to Dr. Michael Aldrich, Department of Neurology, Taubman Center 1920/0316, University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109–0316.

Supported by the American Narcolepsy Association and USPHS Grant AGO8671.

Presented in part at the 43rd annual meeting of the American Academy of Neurology, Boston, MA, April 1991.

Received April 24, 1991. Accepted for publication in final form July 22, 1991.




This article has been cited by other articles:


Home page
BrainHome page
M. A. Piggott, E. F. Marshall, N. Thomas, S. Lloyd, J. A. Court, E. Jaros, D. Burn, M. Johnson, R. H. Perry, I. G. McKeith, et al.
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution
Brain, August 1, 1999; 122(8): 1449 - 1468.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. M. Siegel, R. Nienhuis, S. Gulyani, S. Ouyang, M. F. Wu, E. Mignot, R. C. Switzer, G. McMurry, and M. Cornford
Neuronal Degeneration in Canine Narcolepsy
J. Neurosci., January 1, 1999; 19(1): 248 - 257.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by AAN Enterprises, Inc.